Table 1 Characteristics of study participants in the discovery and replication cohorts
Discovery cohort | Lifelines | EGEA | |||||||
|---|---|---|---|---|---|---|---|---|---|
PersA (n = 49) | ClinR (n = 54) | ComR (n = 20) | PersA (n = 99) | ClinR (n = 25) | Healthy (n = 636) | PersA (n = 106) | ClinR (n = 15) | ComR (n = 3) | |
Characteristics at last visit | |||||||||
Age at remission status, years | 49.8 (48.5; 51.3) | 50.5 (48.3; 57.6) | 50.5 (48.4; 59.8) | 46.9 (40.7;50.7) | 43.2 (35.7;50.3) | 46.3 (39.2;52.9) | 52.6 (36.7; 61.4) | 49.2 (36.7; 57.6) | 30.5 (28.2; 59.1) |
Male, n (%) | 31 (63.3%) | 37 (68.5%) | 15 (75.0%) | 58 (58.6%) | 10 (40.0%) | 384 (60.4%) | 49 (46.7%) | 7 (46.7%) | 1 (33.3%) |
Duration of follow-up, years | 39 (38;40.5) | 39 (37; 42) | 39 (37;41) | 11.3 (10.7; 12.1) | 11.6 (10.7; 12.2) | 11.6 (10.0; 12.7) | |||
Current-smoking, n (%) | 4 (8.2%) | 8 (14.8%) | 2 (10.0%) | 27 (27.3%) | 14 (56.0%) | 207 (32.5%) | 10 (9.5%) | 2 (13.3%) | 1 (33.3%) |
Ex-smoking, n (%) | 13 (26.5%) | 18 (33.3%) | 7 (35.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 35 (33.3%) | 5 (33.3%) | 0 |
Never-smoking, n (%) | 32 (65.3%) | 28 (51.9%) | 11 (55.0%) | 72 (72.7%) | 11 (44.0%) | 429 (67.5%) | 60 (57.1%) | 8 (53.3%) | 2 (66.7%) |
ICS, n (%) | 31 (63.3%) | 0 | 0 | 48 (48.5%) | 0 (0.0%) | 0 (0.0%) | 72 (70.6%) | 0 | 0 |
Allergic rhinitis, n (%) | 33 (67.3%) | 30 (55.6%) | 9 (45.0%) | 59 (59.6%) | 13 (52.0%) | 123 (19.3%) | 70 (67.3%) | 11 (73.3%) | 2 (66.7%) |
BMI | 25.7 (23.7; 28.5) | 26.8 (23.7; 28.3) | 26.0 (22.8; 28.6) | 25.7 (22.9;28.0) | 26.0 (23.7;29.6) | 25.8 (23.6;28.1) | 23.9 (22.4; 27.5) | 22.5 (19.9; 28.0) | 22.0 (19.9; 22.4) |
FEV1% pred | 80.6 (71.1; 91.9) | 90.2 (82.9; 104.7) | 101.8 (85.9; 110.0) | 81.2 (70.9;91.6) | 87.1 (74.0;93.4) | 101.5 (96.1;108.7) | 87.0 (71.7; 98.4) | 95.2 (87.5; 107.2) | 97.5 (90.7; 121.5) |
FVC% pred | 94.2 (88.4; 103.7) | 101.7 (95.2; 111.5) | 106.6 (101.2; 115.9) | 94.1 (85.8;102.2) | 100.3 (90.4;109.2) | 104.0 (97.5;111.4) | 98.5 (84.8; 108.9) | 95.2 (86.9; 106.1) | 96.3 (86.9; 119.2) |
FEV1/FVC | 0.67 (0.60; 0.72) | 0.72 (0.68; 0.75) | 0.72 (0.68; 0.76) | 0.67 (0.62;0.76) | 0.67 (0.62;0.76) | 0.79 (0.75;0.83) | 0.69 (0.61; 0.77) | 0.81 (0.78; 0.82) | 0.80 (0.80; 0.91) |
Characteristics at baseline | |||||||||
Age, years | 10.0 (9.0; 11.0) | 11.0 (9.0; 17.5) | 11.5 (9.8; 15.8) | 40.6 (25.7; 48.7) | 37.0 (26.0; 46.0) | 18.9 (18.8; 46.4) | |||
FEV1% pred | 76.6 (67.4; 84.0) | 77.1 (67.5; 83.8) | 78.1 (73.5; 83.7) | 81.7 (66.2; 95.9) | 90.6 (82.0; 103.0) | 82.0 (80.1; 122.9) | |||
FVC% pred | 88.8 (84.0; 96.1) | 88,3 (80.9; 95.3) | 88.9 (79.8; 96.5) | 95.5 (83.7; 104.3) | 86.4 (81.9; 100.6) | 84.5 (70.1; 118.8) | |||
FEV1/FVC | 0.73 (0.64; 0.78) | 0.73 (0.66; 0.79) | 0.77(0.66; 0.80) | 0.70 (0.63; 0.80) | 0.86 (0.82; 0.89) | 0.86 (0.83; 0.96) | |||
Start asthma before age 16, n (%) | 48 (98.0%) | 50 (92.6%) | 19 (95.0%) | 59 (62.1%) | 18 (81.8%) | 52 (49.5%) | 8 (53.3%) | 2 (66.7%) | |